Bovine Coronavirus Moves to the Centre of UK Calf Health Planning as Screening Finds 69.5% Antibody Prevalence

New MSD Animal Health screening data covering 1,732 UK calves tested between 2022 and 2026 has found bovine coronavirus antibodies in 69.5% of animals, with coronavirus-positive groups significantly more likely to also test positive for PI3 and Mannheimia haemolytica. The findings reinforce the multi-pathogen character of bovine respiratory disease and are pushing BCoV from a peripheral consideration to a central component of UK calf health planning.

Bovine respiratory disease costs the UK beef and dairy sectors approximately £80 million annually, with affected beef animals losing more than 200g per day in liveweight gain. The scale of that loss has driven growing interest in understanding which pathogens are actually circulating on individual units rather than treating BRD as a single undifferentiated condition.

MSD’s subsidised screening service uses ELISA testing on blood samples from calves aged three to six months, processed at a Netherlands laboratory, checking for five major respiratory pathogens. The results allow veterinary surgeons to tailor vaccination protocols and management interventions to the specific pathogen profile present on farm rather than applying generic programmes.

The 69.5% prevalence figure is consistent with earlier UK evidence. Serology from 59 farms with a documented respiratory disease history returned 91.5% positivity for BCoV, indicating the pathogen is widespread across units already experiencing clinical problems.

On the intervention side, company data covering 217 male veal calves indicated vaccinated animals were 2.88kg heavier after ten weeks, with daily liveweight gain 39g higher than unvaccinated controls. The VMD assessment report for Bovilis Nasalgen-C, MSD’s live intranasal vaccine, confirms authorisation from birth, onset of immunity within five days and a duration of immunity of 12 weeks.